Cost-effectiveness analysis of a multicomponent meningococcal serogroup B vaccine in hypothetic epidemic situation in a middle-income country

Files

Cost-effectiveness analysis of a multicomponent meningococcal serogroup B vaccine in hypothetic epidemic situation in a middle-income country.pdf (213.48 KB)

Date

2015

Type:

Artículo

Collections

Artículos Medicina y Ciencias de la Salud

Descargas totales

55

Vistas totales

1
Gestores bibliográficos

Authors

item.contributor.advisor

ORCID:

Journal Title

Journal ISSN

Volume Title

Publisher

Taylor & Francis Group, LLC

item.page.isbn

item.page.issn

item.page.issne

item.page.doiurl

URI

http://hdl.handle.net/11447/305
 http://dx.doi.org/10.1080/21645515.2015.1010885

item.page.extent

item.page.accessRights

item.page.other

item.page.references

Abstract

NmenB vaccine (4CMenB) is now available, but studies on the cost-effectiveness of vaccine introduction in a country outbreak situation are lacking. The aim of this study was to evaluate the cost-effec...

Description

item.page.coverage.spatial

item.page.sponsorship

Citation

Izquierdo G, Torres JP, Santolaya ME, Valenzuela MT, Vega J, Chomali M. Cost-effectiveness analysis of a multicomponent meningococcal serogroup B vaccine in hypothetic epidemic situation in a middle-income country. Hum Vaccin Immunother. 2015;11(4):875-83

Keywords

Meningococcal disease , Meningococcal vaccine , Cost-effectiveness analysis , Outbreak

item.page.dc.rights

item.page.dc.rights.url

Estadísticas de uso
1 0,8 0,5 0,3 0
Agosto 2025Septiembre 2025Octubre 2025Noviembre 2025Diciembre 2025Enero 2026Febrero 2026

Implementado por OpenGeek Services